Aktis Oncology(US:AKTS)2026-03-09 18:42Aktis Oncology Conference Call Summary Company Overview - Company: Aktis Oncology - Focus: Targeted radiopharmaceuticals aimed at transforming anti-cancer medicines, particularly for patients lacking existing radiopharmaceutical options [3][4] Core Industry Insights - Radiopharmaceuticals: The industry is at an inflection point similar to antibody-drug conjugates (ADCs) five years ago, with significant opportunities for new products [4] - Target Space: The current market has limited approved medicines, presenting a "white space opportunity" for new entrants [4] Key Programs and Targets - Lead Program 1189 (Nectin-4): - Target: Nectin-4, expressed in various cancers including bladder, breast, lung, cervical, head and neck, and colorectal cancers [18] - Clinical Validation: Supported by existing data from PADCEV, a validated treatment for bladder cancer [19] - Patient Impact: Aims to provide a radiopharmaceutical option for large patient populations currently without one [18][19] - Second Program 2519 (B7-H3): - Target: B7-H3, expressed in lung and prostate cancers, among others [36] - Competitive Landscape: While there are existing ADCs targeting B7-H3, Aktis aims to differentiate with a unique isotope (Actinium-225) and a non-overlapping toxicity profile [36][37] Clinical Development and Data - Imaging Data: Initial human imaging data for both programs showed high tumor uptake and favorable dosimetry profiles, suggesting a strong therapeutic index [27][29] - Phase 1b Studies: Ongoing dose escalation studies for both programs, with updates expected throughout the year [32][38] Supply Chain and Manufacturing - End-to-End Supply Chain: Aktis has developed its own supply chain capabilities, including a GMP manufacturing facility expected to open by the end of the year [10][11] - Actinium Supply: Multiple supply deals in place to ensure a robust supply of Actinium-225 [15] Partnerships and Collaborations - Collaboration with Eli Lilly: Focused on discovery capabilities for novel miniprotein radioconjugates, with successful milestone achievements ahead of schedule [12][13] - Business Development Strategy: Emphasis on retaining economic rights to lead programs while exploring partnerships that enhance shareholder value [46] Financial Position - IPO Proceeds: Raised $340 million in net proceeds from the IPO, with a cash runway projected into 2029, supporting ongoing clinical development [49][50] Conclusion - Strategic Positioning: Aktis Oncology is well-positioned in the radiopharmaceutical space with a strong pipeline, innovative technology, and a solid financial foundation, aiming to address significant unmet needs in cancer treatment [16][50]